Intensive Care Unit Syndrome, Post-intensive Care Syndrome, Cognitive Disorder
Conditions
Brief summary
Cognitive disorders are common after intensive care. Currently, their diagnosis is based on clinical tests. The investigators plan to study the relationship between different neurological blood biomarkers (cytokines, S100β protein, neuron specific enolase, total Tau protein and neurofilament light chain) and the occurrence of cognitive disorders during the three months following intensive care discharge.
Interventions
OTHERBlood analysis
Blood analysis for neurological biomarkers measurements
OTHERCognitive tests
Questionnaires assessing cognitive function
Sponsors
University of Liege
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Anticipated ICU stay of at least 7 days for sepsis, acute respiratory distress syndrome, severe burns * French speaking
Exclusion criteria
* hearing loss or blindness * mental retardation * known cognitive disorders or dementia * ICU admission for neurological disease * refusal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood neurological biomarkers levels | ICU Admission | Measurement of blood levels of S100β protein |
| Cognitive disorders assessment (global assessment) | the day after ICU discharge | Administration of the MOCA questionnaire (Montreal Cognitive Assessment) : scoring from 0 to 30, the highest score meaning the better cognitive outcome) |
| Memory disorder assessment | 3 months after ICU discharge | Administration of the California Verbal Learning Test: a Z-score will be used to score this item |
| Speed of information processing assessment | 3 months after ICU discharge | Administration of the Ways IV test (a Z-score will be used to score this item) |
| Executive function assessment | 3 months after ICU discharge | Administration of the Trail Making Test (a Z-score will be used to score this item) |
Countries
Belgium
Contacts
Primary ContactAnne-Françoise Rousseau, MD, PhD
Outcome results
None listed